Q3 (2022) Wrap-Up: Insights, Blogs, Trending Content & more
11 October 2022
By Mark Laurie

Don’t miss the next edition!

Sign up to our newsletter and automatically receive our quarterly wrap-ups, insights & news 📨

Welcome to the OracleBio Q3 2022 Wrap-Up.

In this edition, we wrap up all our highlights from the previous 3 months.

There’s a lot to cover, so grab a tea or coffee! ☕

Your content goes here. Edit or remove this text inline or in the module Content settings. You can also style every aspect of this content in the module Design settings and even apply custom CSS to this text in the module Advanced settings.

Trending Content


Utilizing AI to improve analysis accuracy and turnaround time for Preclinical tumor model IHC studies

Lorcan Sherry — Chief Scientific Officer at OracleBio, shares a case study where we utilized AI deep learning techniques to improve the accuracy and turn-around time for quantification of cytotoxic T-cell (CD8 marker), macrophage (F4/80 marker), and vasculature (CD31 marker) IHC staining in viable tumor across n=10 different syngeneic tumor models.

Read the Blog (4 minuted read)


The use and value of the preclinical Bleomycin model in Drug Development for Idiopathic Pulmonary Fibrosis (IPF)

In this article, we collaborated with one of our partners, TherapeutAix, who provide strategic and operational support for drug development projects, to provide our collective thoughts on the use and value of the preclinical Bleomycin model in drug development for Idiopathic Pulmonary Fibrosis (IPF).

Read the Blog (6 minute read)


Behind the Scenes: The Role of R&D in OracleBio

Gabriel Reines March — our R&D Project Manager, explains the role of Research & Development within OracleBio. He shares the motivation behind the launch of our dedicated R&D team last year, its scope, current project insights, and what the future holds.

Read the Blog (6 minute read)


ICOS-Positive Regulatory T Cells in Hepatocellular Carcinoma: The Perspective from Digital Pathology Analysis

The paper, published on Karger, contains work from OracleBio alongside National Taiwan University Hospital and Kymab Ltd (now part of Sanofi).

Read the Blog (2 minute read)

Hot Off the Press

Check out some of our top-rated content from last quarter below, and remember to follow us on LinkedIn and Twitter to stay up to date with all the latest from us.

New: We’re now on YouTube — watch webinars, podcasts & more!

  • Scientific posterUtilizing Quantitative Digital Pathology techniques for analysis of Hepatitis B liver samples stained with a 12-plex multiplex-IF assay
  • Webinar‘Living in a Spatial World’ with Ultivue & Genetic Engineering & Biotechnology News
  • Case Study Integrating Pathologist input in development and validation of a Deep Learning Tissue Classifier App
  • STEM Event OracleBio visit Coatbridge High for an introduction to Digital Pathology and Artificial Intelligence
  • Brochure Check out our new Clinical Tissue Analysis brochure

Image Analysis Tips

Our Image Analysis Scientists share common image analysis Quality Control (QC) issues, and how to solve them.


In our #AskOracleBio series, we answer some of the common questions we get asked via client inquiries, social media, and in reply to our email newsletters to help break down how we work.

Q: “Would OracleBio be prepared to work with our current preferred CROs / Suppliers?”

Yes, this is something we do routinely. We can receive images from you as the Client or directly from your preferred supplier, helping streamline the process as much as possible.


Q: “What information do you need in order to provide me with a quotation?”

We require the number of images, type of staining (IHC/IF/ISH/IMC/Other), number of stains (single, dual, or multiplex), an idea of the expected readouts (cell number, area quantification, spatial analysis, and regions of interest (i.e. tumour or tumour & stroma).


Q: “I’m hesitant about working with an external image analysis partner as it’s not something we’ve done. How do I stay involved and keep track of the study progress?”

We work collaboratively with you throughout the study process. Our online portal allows you to view and interact at each stage of our workflow — from initial QC of images and annotations to cell overlays. Building a close working relationship is very important to us.


Q: “We need support with our study but we are unsure how to get the most value from the Histopathology data?”

Based on our team’s extensive experience, we regularly advise in this area; from histology techniques to the best image analysis approach.

We find a short call to discuss your study extremely valuable as this helps us (and you) better understand the study requirements and goals.

Have a question for us? We’d love to hear from you!

I hope you enjoyed this quarter’s wrap-up!

If you’d like to find out more about any of the topics covered or would like to arrange a chat with our experts regarding a study, please don’t hesitate to get in touch.

And if you’d like to receive our newsletter automatically in the future, don’t forget to sign up.


Mark and the OracleBio team

Karen McClymont

About the author: 

Mark Laurie — Marketing Manager at OracleBio

With over a decade in senior marketing and sales roles within the IT, technology, and entertainment sectors, Mark brings a fresh perspective and unique skill set to lead OracleBio’s global marketing and communications efforts; helping share our story and build our community.

Find out about OracleBio's Pathology Expertise

Learn about our GCP Image Analysis Services

Speak to our experts

Planning your study and need advice on your image analysis? We’d love to chat!